• Zelluna launched an accelerated bookbuild for a private placement of new shares, targeting gross proceeds of NOK 45-50 million.
• Subscription price to be set through the bookbuilding process; pre-commitments total about NOK 35 million from existing shareholders.
• Parallel Norway-only retail offering via Nordnet aims to raise up to the NOK equivalent of EUR 1 million at the same price.
• Proceeds earmarked for the Phase 1 study of ZI-MA4-1, broader TCR-NK platform development, general corporate purposes.
• Bookbuild runs from 16:30 CEST today to 08:00 CEST June 18; initial clinical data expected from mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606171046OMX_____CNEWS_EN_GNW1001188292_en) on June 17, 2026, and is solely responsible for the information contained therein.